4 edition of Quinolinic acid and the kynurenines found in the catalog.
Includes bibliographies and index.
|Statement||editor, Trevor W. Stone.|
|Contributions||Stone, T. W.|
|LC Classifications||QP563.K9 Q56 1989|
|The Physical Object|
|Pagination||307 p. :|
|Number of Pages||307|
|LC Control Number||88039981|
Levels of the excitotoxin quinolinic acid (QUIN) were measured in the cerebrospinal fluid of infants and children with congenital hyperammonemia. Twofold to tenfold elevations of QUIN were found in 4 neonates in hyperammonemic coma (QUIN range, – nM; control mean, ± 90 nM; p. Substantial increases in the tryptophan-kynurenine pathway metabolites, l-kynurenine and the neurotoxin quinolinic acid, occur in human brain, blood and systemic tissues during immune activation. Studies in vitro have shown that not all human cells are capable of synthesizing by:
Quinolinic acid (QUIN) is an endogenous N-methyl-D-aspartate receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and by: Quinolinic acid is a pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of has a role as a NMDA receptor agonist, a human metabolite, a mouse metabolite and an Escherichia coli metabolite. It is a conjugate acid of a quinolinate(1-) .
Currently we are trying to develop methods of HPLC analysis for the kynurenine pathway metabolites, however we are having difficulties in the case of quinolinic acid. Kynurenines are the products of tryptophan metabolism. Among them, kynurenine and kynurenic acid are generally thought to have neuroprotective properties, while 3-hydroxykynurenine, 3-hydroxyanthranilic acid and quinolinic acid are considered neurotoxic. They participate in immunoregulation and inflammation and possess pro- or anti-excitotoxic properties, and their involvement in oxidative Cited by:
justice of God in the damnation of sinners
Guarding the line and other original poems.
A new dawn for the Dark Age?
Guidance notes for the implementation of small scale packaged combined heat and power
Rulers feeding & guiding their people, with integrity & skilfulness.
Hh-Whn Dino Rul Er-Rid
Measured changes in C-band radar reflectivity of clear air caused by aircraft wake vortices
Exposing the Enemy
Coping with stress
J.J. Giambiagi festschrift
Hayton Greene Park
Appeasing or resisting the oppressor
Opening of the new premises, June 23, 1894.
Long-term trends in benthos abundance and persistence in the Upper Sacramento-San Joaquin Estury
Strategy for the South East
Contributors present an up-to-date overview of existing knowledge of quinolinic acid and other kynurenines. Topics covered include: kynurenines in the CNS, kynurenine and lysosomal proteolysis, pharmacology of the kynurenine pathway, retinal actions of quinolinic and kynurenic acids, behavioral and convulsive effects, the affective disorders, skin, hepatic encephalopathy, and invertebrates.
Additional Physical Format: Online version: Quinolinic acid and the kynurenines. Boca Raton, Fla.: CRC Press, © (OCoLC) Document Type. Quinolinic acid (QUIN), a neuroactive metabolite of the kynurenine pathway, is normally presented in nanomolar concentrations in human brain and cerebrospinal fluid (CSF) and is often implicated in the pathogenesis of a variety of human neurological by: Marked increases in metabolites of the L-tryptophan-kynurenine pathway, L-kynurenine and quinolinic acid (Quin), were observed in serum and cerebrospinal fluid (CSF) of both the rat and human with.
Quinolinic acid (2,3-pyridinedicarboxylic acid; QUIN) is an intermediate of the kynurenine metabolic pathway of the amino acid, tryptophan. This pathway is primarily responsible for NAD(P) + production .The key intermediate kynurenine reacts further by forming (1) quinoline derivatives, and (2) pyridine derivatives, including QUIN, which can be metabolized further to nicotinic by: 1.
Pharmacological actions of metabolites in the kynurenine pathway Quinolinic acid. The kynurenine pathway for the oxidative metabolism of tryptophan includes several compounds which have the ability to increase or decrease oxidative stress and which are, therefore, prime targets for therapeutic interventions designed to combat disorders involving tissue damage and by: 3.
Initially, the major subjects of our pharmacological experiments on mice and rats were the interaction with monoamines (Lapin, –) and the convulsant effect of quinolinic acid (QUIN) and kynurenine (KYN) as well as their excitatory action (Lapin, a, b,) and the anticonvulsant effect of kynurenic (KYNA), picolinic and.
In theory, quinolinic acid could be formed in the brain in several ways: (1) from tryptophan, as in macrophages and in liver; (2) from kynurenine or 3-hydroxykynurenine which, having been formed peripherally, cross the blood-brain barrier to undergo final conversion to quinolinic acid by brain KH, kynureninase, and HAD; or (3) from peripherally.
By testing other compounds in the kynurenine pathway, a second metabolite, kynurenic acid, was later characterized as a glutamate receptor antagonist, blocking the actions of glutamate, NMDA and quinolinic acid, as well as related agonists thought to define other glutamate receptor subtypes, namely quisqualic acid [acting at what are now known.
The kynurenine pathway of tryptophan metabolism is an area of growing interest for NI and has received much attention in recent years,31–33 Throughout the body, including the CNS, the primary fate of tryptophan is conversion to l-kynurenine.
In turn, l-kynurenine is processed into several metabolites including kynurenic acid (KYNA) and quinolinic acid (QUIN) that subsequently activate or inhibit. Until quinolinic acid was believed to be a physiologically inactive metabolite of tryptophan; a mere intermediate along the kynurenine pathway in the synthesis of the essential co-factors nicotinic acid and nicotinamide adenine potential physiological and pharmacological significance of quinolinic acid was recognised with the discovery of its ability to activate Cited by: The essential amino acid tryptophan is not only a precursor of serotonin but is also degraded to several other neuroactive compounds, including kynurenic acid, 3-hydroxykynurenine and quinolinic acid.
Summary. Quinolinic acid is an endogenous compound with actions on the NMA receptor to produce neuronal excitation, toxicity and convulsions.
It does not appear to be taken up by membrane transport processes in the brain, and it may therefore function as a long term modulator of neuronal excitability rather than as a classical neurotransmitter. implicated. Quinolinic acid (QUIN) is an endogenous N-methyl-D-aspartate receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating W.
l-Kynurenine is a metabolite of the amino acid l-tryptophan used in the production of niacin. Kynurenine is synthesized by the enzyme tryptophan dioxygenase, which is made primarily but not exclusively in the liver, and indoleamine 2,3-dioxygenase, which is made in many tissues in response to immune activation.
Kynurenine and its further breakdown products carry out diverse biological. Quinolinic acid is a heterocyclic amino acid that selectively activates the neuronal NMDA subtype of glutamate receptors.
19 Within the brain, quinolinic acid concentrations are normally lower compared to blood and systemic tissues as tryptophan is metabolized to 5-hydroxytryptamine rather than to formylkynurenine.
86 However, during an immune response, either systemic or central, IDO-1 activity and levels of quinolinic acid Cited by: Quinolinic Acid Anthranilic Acid Kynurenine Pathway Tryptophan Depletion Tryptophan Metabolite These keywords were added by machine and not by the authors.
This process is experimental and the keywords may be updated as the learning algorithm improves. Elevation of quinolinic acid concentrations in cerebrospinal fluids has been seen in several neurodegenerative diseases, and injection of exogenous quinolinic acid can cause neurodegeneration in mice.
The kynurenine pathway can be stimulated in the brain by treatment with by: Abstract:Introduction: The kynurenine pathway includes several neuroactive compounds, including kynurenic acid, picolinic acid, 3-hydroxykynurenine and quinolinic acid.
The enzymatic cascade of the kynurenine pathway is tightly connected with the immune system, and may provide a link between the immune system and neurotransmission.
The kynurenine pathway is a metabolic pathway leading to the production of nicotinamide adenine dinucleotide (NAD+), as well as other active metabolites, from the degradation of tryptophan, an essential amino tion in the pathway is associated with certain genetic disorders.
Quinolinic acid (abbreviated QUIN or QA), also known as pyridine-2,3-dicarboxylic acid, is a dicarboxylic acid with a pyridine backbone. It is a colorless solid. It is the biosynthetic precursor to nicotine. Quinolinic acid is a downstream product of the kynurenine pathway, which metabolizes the amino acid tryptophan.
It acts as an NMDA receptor al formula: C₇H₅NO₄. Quinolinic acid is a neurotoxic substance produced by our own bodies. High levels may be the cause of the foggy headed, forgetful, depressive 'lyme brain' some lyme patients complain of. high levels are associated with mental illness, ALS, alzheimers, depression etc.L-kynurenine, the central agent of this pathway, can be converted into two other important compounds: the neuroprotective kynurenic acid and the neurotoxic quinolinic acid.
Kynurenines have been.